---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-016427"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2021-07-08T23:59:59+00:00"
generated_at: "2026-06-30T06:32:32.174632+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nephros reports preliminary Q2 2021 revenue $2.2M (+40% YoY); submits HDF product for FDA 510(k) clearance

## Summary
- Preliminary Q2 2021 net revenue ~$2.2M, >40% year-over-year increase.
- Six-month revenue >$5M, up 20% vs same periods in 2020 and 2019.
- Subsidiary SRP submitted HDF Assist Module for FDA 510(k) clearance; commercial launch planned at limited dialysis clinics.
- Pathogen Detection Systems segment generated >$50k in Q2 from on-site testing services.
- Consolidated cash at quarter end ~$8.3M.

## SEC filing metadata
- accession: 0001493152-21-016427
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2021-07-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315221016427/0001493152-21-016427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315221016427/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-016427
- JSON: https://secwatch.observer/filing/0001493152-21-016427.json
- Plain text: https://secwatch.observer/filing/0001493152-21-016427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.